Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/17990195
Conclusion of this study
It is concluded that the standardized extract SHR-5 shows anti-depressive potency in patients with mild to moderate depression when administered in dosages of either 340 or 680 mg/day over a 6-week period.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study
